Compare IONQ Inc (IONQ) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IONQ Inc vs Repligen Corporation Common Stock — how do they compare? IONQ Inc trades at $30.8 (market cap $14.07B), while Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B). The key difference: IONQ Inc is the larger of the two by market cap, and Repligen Corporation Common Stock is trading nearer its 52-week high, IONQ Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold IONQ Inc for 34 Days and Repligen Corporation Common Stock for 0 Days on average.
| IONQ | RGEN | |
|---|---|---|
Market Cap | $14.07B | $11.14B |
Volume | 23,412,195 | 1,259,263 |
Sector | Technology | Health |
52-Week High | $72.41 | $194.57 |
52-Week Low | $26.59 | $102.87 |
Typical Hold Time | 34 Days | 0 Days |
Enterprise Value | $12.01B | $11.02B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IONQ trades at $34.73, down 4.25% today, with a bearish technical signal despite recent earnings beats. The quantum computing company shows explosive revenue growth (2025: $130M, 2026: $246M) but faces significant profitability challenges with a -553% net income margin. Analyst consensus is split with a $65.20 price target suggesting 88% upside potential, while technical indicators show oversold conditions with RSI at 26.86.
The stock presents high-risk, high-reward potential with Wall Street divided on its path to profitability. Key catalysts include quantum technology adoption and manufacturing scaling, while risks center on cash burn and competitive threats in the emerging quantum computing space.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IONQ Inc
IonQ is a leader in quantum computing, developing world-class quantum systems. Its technology aims to solve complex problems across finance, healthcare, and materials science that are beyond classical computers.
Read more on IONQ →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
